Recombinant Staphylococcus aureus Serine hydroxymethyltransferase (glyA)

What is Staphylococcus aureus Serine Hydroxymethyltransferase (glyA)?

Staphylococcus aureus Serine Hydroxymethyltransferase (SHMT), encoded by the glyA gene (also referred to as shmT in some literature), is a critical enzyme that catalyzes the reversible interconversion of serine and glycine with tetrahydrofolate (THF) serving as the one-carbon carrier . This enzyme belongs to the broader SHMT family and plays an indispensable role in one-carbon metabolism, which is essential for various biosynthetic pathways in bacterial cells . Recent studies have also identified SHMT as a key factor in lysostaphin resistance, expanding its significance beyond metabolic functions to antimicrobial resistance mechanisms .

What is the molecular structure and biochemical function of S. aureus SHMT?

S. aureus SHMT is a protein consisting of 412 amino acids with a molecular mass of approximately 45.2 kDa, as characterized in the Mu3/ATCC 700698 strain . The enzyme primarily functions as a pyridoxal phosphate-dependent enzyme catalyzing two distinct reactions:

• THF-dependent interconversion of serine and glycine, which generates one-carbon units essential for the biosynthesis of purines, thymidylate, methionine, and other important biomolecules .

• THF-independent aldolase activity toward beta-hydroxyamino acids, producing glycine and aldehydes via a retro-aldol mechanism .

These dual functionalities position SHMT at a crucial junction in bacterial metabolism, linking amino acid metabolism with nucleotide biosynthesis and other essential pathways.

How does SHMT activity integrate with cellular metabolism in S. aureus?

SHMT functions as a metabolic hub in S. aureus, connecting several critical pathways. The enzyme's primary role in serine/glycine interconversion directly links to folate metabolism, which provides one-carbon units for nucleotide synthesis and methylation reactions . Research has shown that SHMT is particularly important in environment-specific metabolic adaptations. Transposon sequencing analyses have identified glyA among the genes significantly enriched for importance during S. aureus infection in airway models, indicating its crucial role in infection-specific metabolism . The enzyme appears to be part of the metabolic network that enables S. aureus to adapt to diverse host environments, supporting both growth and stress tolerance required for successful pathogenesis.

What methods are effective for producing functional recombinant S. aureus SHMT?

Production of functional recombinant S. aureus SHMT requires careful consideration of expression systems and purification strategies. Based on experimental approaches described in the literature, a recommended protocol includes:

• Gene cloning: Amplify the glyA gene from S. aureus genomic DNA using PCR with specific primers containing appropriate restriction sites.

• Expression vector selection: Clone the glyA gene into a suitable expression vector (such as pET or pBAD series) with an affinity tag (His-tag is commonly used).

• Expression conditions: Transform into E. coli BL21(DE3) or similar expression strains. Induce protein expression at lower temperatures (16-25°C) rather than 37°C to improve solubility.

• Purification: Use immobilized metal affinity chromatography (IMAC) followed by size exclusion chromatography to obtain high-purity protein.

• Activity verification: Confirm enzyme functionality through spectrophotometric assays measuring the conversion of serine to glycine or reverse .

Researchers should carefully monitor the presence of the pyridoxal phosphate cofactor, which is essential for SHMT activity, and consider adding it during purification or enzyme assays if necessary.

How can researchers generate and characterize SHMT mutants in S. aureus?

Generation of SHMT mutants (ΔshmT) in S. aureus requires precise genetic manipulation techniques. A methodological approach based on successful studies includes:

• Allelic replacement strategy:

  • Construct a deletion plasmid containing upstream and downstream regions flanking the shmT gene

  • Transform into S. aureus using electroporation

  • Select for integration and then counterselect for plasmid excision

  • Confirm deletion by PCR and sequencing

• Complementation strategy:

  • Clone the intact shmT gene into a shuttle vector with a suitable promoter

  • Transform the construct into the ΔshmT strain

  • Select transformants on appropriate antibiotics

  • Verify expression by qRT-PCR or Western blotting

• Phenotypic characterization:

  • Assess growth rates in different media

  • Evaluate lysostaphin sensitivity through minimum inhibitory concentration (MIC) assays and time-kill curves

  • Analyze metabolic profiles using targeted metabolomics

  • Assess virulence in appropriate in vitro and in vivo models

This systematic approach allows for comprehensive analysis of SHMT's role in S. aureus physiology and pathogenesis.

What assays are available for measuring S. aureus SHMT enzymatic activity?

Several robust assays can be employed to measure SHMT enzymatic activity in recombinant preparations or S. aureus lysates:

• Spectrophotometric coupled assays:

  • Measure the formation of 5,10-methylene-THF through coupling with NADPH oxidation

  • Monitor absorbance changes at 340 nm

  • Calculate enzyme kinetics parameters (Km, Vmax)

• Radiometric assays:

  • Use 14C-labeled serine as substrate

  • Quantify conversion to [14C]glycine and [14C]formaldehyde

  • Separate products by thin-layer chromatography or HPLC

• HPLC-based assays:

  • Directly quantify serine depletion and glycine formation

  • Use derivatization for improved detection sensitivity

  • Allow for precise measurement of reaction stoichiometry

• Microbiological assays:

  • Assess functional complementation in glycine auxotrophs

  • Measure growth restoration as an indicator of SHMT activity

These methods can be adapted to investigate specific aspects of SHMT function, including effects of inhibitors, substrate specificity, and cofactor requirements .

How does SHMT contribute to lysostaphin resistance in S. aureus?

SHMT has been identified as a key player in lysostaphin resistance in S. aureus through comprehensive genomic and functional analyses. The mechanism appears to involve:

• Alteration of cell wall composition: SHMT activity likely influences peptidoglycan architecture, particularly the pentaglycine cross-bridges that are targets for lysostaphin .

• Functional evidence: Knockout studies demonstrated that ΔshmT mutants become susceptible to lysostaphin, while complementation with the shmT gene restores resistance . This direct genetic evidence confirms SHMT's role in the resistance mechanism.

• Metabolic linkage: The enzyme's function in one-carbon metabolism and its connection to folate pathways suggests it may influence cell wall precursor synthesis or modification, thereby affecting lysostaphin's ability to cleave pentaglycine bridges .

This discovery is particularly significant as it reveals a previously unknown resistance mechanism against lysostaphin, an antimicrobial that targets the staphylococcal cell wall structure.

What is the relationship between SHMT function and cell wall integrity?

SHMT function appears to be intricately linked to cell wall integrity in S. aureus through several possible mechanisms:

• Cell wall composition: SHMT's role in glycine metabolism may directly impact the synthesis of pentaglycine bridges, which are essential components of S. aureus peptidoglycan .

• Cell wall flexibility and stiffness: Research on S. aureus cell wall properties has shown that alterations in cross-linking significantly affect cell wall stiffness . Given SHMT's influence on lysostaphin resistance (which targets cross-links), it may modulate cell wall mechanical properties.

• Interaction with peptidoglycan hydrolases (PGHs): S. aureus possesses at least 18 different PGHs that continuously remodel the peptidoglycan network during growth and division . SHMT activity may influence this remodeling process through metabolic interactions.

• Stress response integration: SHMT might contribute to hypoxic and stress responses that are known to affect cell wall synthesis and integrity, as seen with other metabolic pathways in S. aureus .

Understanding these connections provides valuable insights for targeting cell wall biosynthesis as an antimicrobial strategy.

Can SHMT inhibition potentiate the effectiveness of existing antimicrobials?

Emerging evidence suggests that SHMT inhibition could potentially enhance the effectiveness of existing antimicrobials against S. aureus, particularly those targeting cell wall integrity:

• Lysostaphin sensitization: Since ΔshmT mutants show increased susceptibility to lysostaphin, SHMT inhibitors could potentially restore sensitivity in resistant strains .

• Synergistic potential: SHMT inhibition might be synergistic with β-lactam antibiotics and other cell wall-active agents by compromising the cell's ability to maintain cell wall integrity under antibiotic stress.

• Metabolic vulnerability: As a key enzyme in one-carbon metabolism, SHMT inhibition could create metabolic bottlenecks that increase bacterial susceptibility to various stresses, including antibiotic exposure.

• Experimental approach for testing this hypothesis:

  • Screen for small molecule SHMT inhibitors using recombinant enzyme assays

  • Evaluate minimum inhibitory concentration (MIC) of antimicrobials alone and in combination with SHMT inhibitors

  • Assess synergy using checkerboard assays and time-kill curves

  • Validate findings in relevant in vivo infection models

This approach represents a promising strategy for developing combination therapies against resistant S. aureus strains.

How does SHMT contribute to one-carbon metabolism and nucleotide synthesis?

SHMT plays a central role in one-carbon metabolism in S. aureus, serving as a key source of one-carbon units required for numerous biosynthetic pathways:

• THF-dependent pathway: The enzyme catalyzes the conversion of serine to glycine, transferring a methylene group to tetrahydrofolate to form 5,10-methylene-THF . This reaction is bidirectional but often favors serine catabolism in bacterial systems.

• Contribution to nucleotide synthesis: The one-carbon units generated by SHMT are essential for:

  • Purine synthesis - contributing to C2 and C8 of the purine ring

  • Thymidylate synthesis - providing the methyl group for conversion of dUMP to dTMP

  • These connections explain why glyA appears in studies identifying genes important for S. aureus survival in host environments .

• Integration with folate metabolism: SHMT activity is directly linked to folate cycle enzymes, forming a metabolic network that channels one-carbon units to various biosynthetic pathways .

• Metabolic flexibility: The reversible nature of the SHMT reaction allows S. aureus to adapt to changing nutritional environments by either generating or consuming glycine and one-carbon units as needed.

This metabolic centrality makes SHMT a critical enzyme for S. aureus growth and adaptation to diverse environmental conditions.

What metabolomic approaches can reveal SHMT's impact on S. aureus physiology?

Advanced metabolomic techniques can provide comprehensive insights into SHMT's impact on S. aureus metabolism:

• Targeted metabolomics approach:

  • Focuses on direct SHMT substrates and products (serine, glycine, folate derivatives)

  • Quantifies changes in amino acid pools using LC-MS/MS

  • Measures folate-dependent one-carbon metabolites

  • Assesses nucleotide precursors and end products

• Untargeted metabolomics workflow:

  • Global metabolic profiling comparing wild-type and ΔshmT strains

  • Identifies unexpected metabolic alterations beyond direct pathway connections

  • Reveals adaptive responses to SHMT perturbation

  • Discovers novel metabolic interactions

• Flux analysis techniques:

  • Uses 13C-labeled substrates to trace carbon flow through metabolic networks

  • Measures actual pathway activities rather than just metabolite levels

  • Quantifies the relative contribution of SHMT to various biosynthetic pathways

  • Provides dynamic rather than static metabolic information

• Integration with transcriptomics:

  • Correlates metabolic changes with transcriptional responses

  • Identifies regulatory mechanisms linking SHMT activity to global metabolism

  • Reveals compensatory pathways activated upon SHMT inhibition

These approaches can help construct a comprehensive metabolic map centered on SHMT, providing insights into its broader physiological roles beyond its primary catalytic function.

How does SHMT function change under different environmental conditions?

SHMT function in S. aureus exhibits remarkable plasticity across different environmental conditions, reflecting its central role in metabolic adaptation:

• Oxygen availability:

  • Hypoxic environments significantly alter S. aureus metabolism

  • SHMT activity may be modulated in response to oxygen limitation

  • This adaptation is particularly relevant during infection, as healthy bone is intrinsically hypoxic, with further decreases in oxygen concentration during S. aureus infection

• Nutrient availability:

  • Amino acid limitation can shift SHMT reaction directionality

  • Glycine-rich environments may favor the reverse reaction (glycine → serine)

  • Serine abundance typically promotes forward reaction and one-carbon unit generation

• Stress conditions:

  • Antimicrobial exposure may upregulate SHMT as part of a broader stress response

  • Metabolic adaptation to host defense mechanisms likely involves SHMT modulation

  • Studies have shown that metabolic genes, including those involved in one-carbon metabolism, are significantly enriched among genes important for S. aureus survival during infection

• Growth phase considerations:

  • SHMT activity may differ between exponential and stationary phases

  • Expression levels can change throughout the bacterial life cycle

  • Integration with cell wall synthesis varies with growth rate

Understanding these environmental adaptations is crucial for developing targeted interventions against S. aureus infections in specific host niches.

What evidence links SHMT to S. aureus virulence and pathogenesis?

Emerging evidence connects SHMT to S. aureus virulence through several mechanisms:

• Infection model findings:

  • Transposon sequencing (Tn-seq) studies have identified glyA among the genes important for S. aureus survival during airway infection

  • Metabolic genes, including those involved in energy production and nucleotide metabolism, are significantly enriched among factors required for successful infection

• Stress response integration:

  • SHMT may contribute to bacterial adaptation to host-imposed stresses

  • The enzyme's role in one-carbon metabolism supports nucleotide synthesis required for rapid replication during infection

• Potential impact on virulence factor production:

  • S. aureus pathogenesis involves coordinated expression of numerous virulence factors

  • Metabolic status influences regulatory networks controlling virulence gene expression

  • SHMT activity may indirectly affect these regulatory pathways through its influence on cellular metabolism

• Role in biofilm formation:

  • Some studies suggest connections between central metabolism and biofilm development

  • SHMT could influence biofilm formation through effects on cell wall properties and metabolic adaptation

While direct mechanistic links between SHMT and virulence factor production require further investigation, the available evidence suggests that SHMT contributes to S. aureus pathogenesis by supporting metabolic adaptation to host environments.

How might SHMT inhibition affect S. aureus virulence in animal models?

SHMT inhibition could potentially attenuate S. aureus virulence in animal models through multiple mechanisms:

• Metabolic vulnerability:

  • Disrupting one-carbon metabolism would impair nucleotide synthesis

  • This could reduce bacterial replication rates in vivo

  • DNA repair mechanisms might be compromised, increasing susceptibility to host-generated oxidative damage

• Cell wall integrity:

  • Given SHMT's connection to lysostaphin resistance and potential impact on cell wall structure

  • Inhibition could weaken the cell wall, enhancing susceptibility to host defense mechanisms

  • Neutrophil-mediated killing might be more effective against SHMT-inhibited S. aureus

• Adaptation to host environments:

  • SHMT appears important for adaptation to specific infection sites

  • Inhibition could impair survival in nutrient-limited or hypoxic host niches

  • Host-imposed stresses might become more detrimental to bacterial survival

• Experimental design for testing this hypothesis:

  • Generate conditional SHMT mutants or employ chemical inhibition approaches

  • Test virulence in multiple infection models (skin, pneumonia, bacteremia)

  • Measure bacterial burden, host survival, and immune response parameters

  • Analyze metabolic profiles of bacteria recovered from infected tissues

These approaches could validate SHMT as an attractive target for anti-virulence strategies.

Could SHMT be targeted as part of a multivalent vaccine strategy?

While SHMT itself has not been specifically mentioned as a vaccine target in the provided search results, theoretical considerations suggest potential applications within a multivalent vaccine approach:

• Current approaches to S. aureus vaccines:

  • Single-component vaccines targeting S. aureus have failed to show efficacy in clinical trials

  • Successful approaches may require targeting multiple virulence factors simultaneously

  • Glycoprotein vaccines combining capsular polysaccharides with protein carriers have shown promise

• SHMT as a potential vaccine component:

  • As a conserved metabolic enzyme, SHMT may be antigenically stable across strains

  • Its connection to cell wall integrity suggests antibodies might enhance cell wall-targeting antimicrobials

  • Combination with established vaccine targets like capsular polysaccharides or alpha toxin could enhance protection

• Experimental approach for evaluation:

  • Express and purify recombinant SHMT without affecting its three-dimensional structure

  • Generate anti-SHMT antibodies and test for neutralizing activity

  • Assess protection in passive immunization models

  • Consider glycoconjugate approach similar to successful strategies with other S. aureus antigens

• Challenges to consider:

  • Limited surface accessibility may reduce antibody binding to native SHMT in intact bacteria

  • Essential metabolic functions might drive rapid selection of escape variants

  • Cross-reactivity with human SHMT could pose safety concerns

While speculative, this approach deserves investigation as part of the ongoing effort to develop effective vaccines against S. aureus.

What structural biology approaches could reveal SHMT's role in lysostaphin resistance?

Advanced structural biology techniques could provide molecular insights into SHMT's unexpected role in lysostaphin resistance:

• X-ray crystallography and cryo-EM studies:

  • Determine high-resolution structures of S. aureus SHMT in different functional states

  • Compare structures with SHMTs from lysostaphin-sensitive strains

  • Identify potential binding partners involved in cell wall metabolism

  • Visualize conformational changes upon substrate or inhibitor binding

• Protein-protein interaction analyses:

  • Use pull-down assays, cross-linking studies, and co-immunoprecipitation to identify SHMT interaction partners

  • Employ bacterial two-hybrid systems to screen for novel interactions

  • Characterize interactions with peptidoglycan synthesis enzymes or regulators

  • Validate interactions using surface plasmon resonance or isothermal titration calorimetry

• Molecular dynamics simulations:

  • Model SHMT dynamics under different conditions

  • Simulate interactions with metabolites and potential binding partners

  • Predict conformational changes that might influence cell wall-related functions

  • Guide the design of specific inhibitors targeting non-catalytic functions

• In situ structural studies:

  • Visualize SHMT localization using super-resolution microscopy

  • Track dynamic changes in localization during cell cycle and under stress

  • Correlate localization with cell wall synthesis machinery

These approaches could reveal whether SHMT influences lysostaphin resistance through direct interactions with cell wall components or indirect metabolic effects.

How do genetic variations in glyA affect S. aureus antimicrobial susceptibility profiles?

Genetic variations in the glyA gene could significantly impact S. aureus antimicrobial susceptibility through several mechanisms:

• Comprehensive sequencing approach:

  • Sequence glyA across diverse clinical isolates with varying antimicrobial resistance profiles

  • Identify natural polymorphisms and correlate with phenotypic differences

  • Focus on isolates with unexplained resistance to cell wall-active agents

  • Perform whole-genome sequencing to identify potential compensatory mutations

• Structure-function analysis:

  • Introduce specific mutations through site-directed mutagenesis

  • Express and characterize variant proteins

  • Measure enzymatic activities and effects on antimicrobial susceptibility

  • Create a comprehensive mutation map linking sequence variations to resistance phenotypes

• Transcriptional regulation investigation:

  • Analyze glyA promoter regions across strains

  • Measure expression levels in different genetic backgrounds

  • Identify regulatory networks controlling glyA expression

  • Assess how expression differences correlate with resistance profiles

• Clinical correlation studies:

  • Collect S. aureus isolates from treatment failures

  • Screen for glyA mutations or expression changes

  • Correlate findings with patient outcomes and treatment histories

  • Develop diagnostic markers for resistance prediction

This systematic approach could reveal how natural variation in SHMT contributes to the diverse antimicrobial resistance profiles observed in clinical S. aureus isolates.

What computational methods can predict novel SHMT inhibitors with antimicrobial potential?

Advanced computational methods can accelerate the discovery of novel SHMT inhibitors with potential antimicrobial applications:

• Structure-based virtual screening:

  • Use crystal structures or homology models of S. aureus SHMT

  • Perform molecular docking of large compound libraries

  • Rank compounds based on binding energy and interaction patterns

  • Prioritize compounds that exploit unique features of bacterial SHMT versus human counterparts

• Pharmacophore modeling:

  • Identify essential chemical features required for SHMT inhibition

  • Develop pharmacophore models based on known inhibitors and substrate interactions

  • Screen virtual libraries for compounds matching the pharmacophore

  • Refine models iteratively based on experimental validation

• Machine learning approaches:

  • Train models on existing enzyme inhibitor datasets

  • Incorporate SHMT-specific structural and functional data

  • Use deep learning to identify novel chemical scaffolds

  • Predict compounds with optimal pharmacokinetic properties

• Fragment-based design:

  • Identify small molecular fragments that bind to different SHMT pockets

  • Link fragments to create compounds with higher affinity and specificity

  • Optimize fragments through iterative computational and experimental cycles

  • Focus on fragments that interact with residues unique to bacterial SHMT

• Experimental validation workflow:

  • Test top computational hits in enzymatic assays

  • Assess antimicrobial activity against S. aureus

  • Determine specificity over human SHMT

  • Measure effects on lysostaphin sensitivity

This integrated computational and experimental approach has the potential to identify novel antimicrobial compounds targeting a metabolic vulnerability in S. aureus.

What emerging technologies could advance our understanding of SHMT's multifunctional roles?

Several cutting-edge technologies hold promise for unraveling SHMT's diverse functions in S. aureus:

• CRISPR interference systems:

  • Develop CRISPRi tools for S. aureus to create tunable glyA knockdown

  • Enable precise temporal control of SHMT expression

  • Study dose-dependent effects on metabolism and resistance

  • Identify genetic interactions through CRISPRi-based synthetic lethality screens

• Single-cell analysis approaches:

  • Investigate cell-to-cell variability in SHMT expression and activity

  • Correlate metabolic heterogeneity with phenotypic diversity

  • Track SHMT dynamics during infection using reporter systems

  • Identify subpopulations with altered antimicrobial susceptibility

• Multi-omics integration:

  • Combine transcriptomics, proteomics, and metabolomics data

  • Apply advanced computational modeling to construct comprehensive metabolic networks

  • Predict system-wide effects of SHMT perturbation

  • Identify non-obvious connections between SHMT and other cellular processes

• In vivo imaging techniques:

  • Develop tools to visualize SHMT activity in live infection models

  • Track metabolic adaptations during host-pathogen interactions

  • Correlate spatial distribution of bacteria with metabolic profiles

  • Measure real-time responses to antimicrobial treatment

These technologies promise to reveal new dimensions of SHMT function and potentially identify novel therapeutic strategies targeting this multifunctional enzyme.

How might combination approaches targeting SHMT improve antimicrobial strategies?

Innovative combination approaches targeting SHMT could create more effective antimicrobial strategies against S. aureus:

• Dual-targeting strategies:

  • Combine SHMT inhibitors with cell wall-active agents like lysostaphin

  • Target both the metabolic and structural roles of SHMT

  • Reduce the likelihood of resistance development through multiple mechanisms

  • Potentially resensitize resistant strains to conventional antibiotics

• Metabolic sensitization approach:

  • Use partial SHMT inhibition to create metabolic vulnerabilities

  • Combine with inhibitors of parallel or compensatory pathways

  • Target adaptation mechanisms that S. aureus employs during infection

  • Design combinations specific to infection sites (e.g., hypoxic environments)

• Immune-antimicrobial combinations:

  • Pair SHMT inhibitors with immune stimulators

  • Enhance neutrophil-mediated killing while compromising bacterial metabolism

  • Target SHMT's potential role in immune evasion

  • Design combination approaches suitable for immunocompromised patients

• Experimental design to evaluate combinations:

  • Perform comprehensive synergy testing using checkerboard assays

  • Evaluate combination efficacy in relevant infection models

  • Monitor resistance development under combination pressure

  • Assess host toxicity and pharmacokinetic compatibility

This multifaceted approach could yield novel therapeutic strategies effective against multidrug-resistant S. aureus strains.

What in vivo models are optimal for studying SHMT's role in S. aureus pathogenesis?

Selection of appropriate in vivo models is crucial for understanding SHMT's role in S. aureus pathogenesis:

• Tissue-specific infection models:

  • Skin/soft tissue infection model: Evaluates SHMT's role in a common S. aureus infection site

  • Pneumonia model: Especially relevant given glyA's importance in airway infection

  • Osteomyelitis model: Allows study of SHMT in hypoxic bone environments

  • Bacteremia/sepsis model: Assesses systemic infection dynamics

• Host factor considerations:

  • Neutrophil depletion studies: Evaluate how neutrophil-imposed stresses interact with SHMT function

  • Genetic knockout mice: Study infections in hosts with altered metabolic or immune functions

  • Humanized mouse models: Better recapitulate human-specific aspects of S. aureus infections

  • Diabetic models: Assess SHMT's role in a clinically relevant comorbidity

• Longitudinal monitoring approaches:

  • In vivo imaging of reporter strains: Track bacterial population dynamics

  • Sequential tissue sampling: Monitor metabolic adaptations over time

  • Simultaneous host-pathogen transcriptomics: Capture interaction dynamics

  • Real-time metabolism assessment: Measure metabolic shifts during infection progression

• Ex vivo systems:

  • Human tissue explants: Bridge the gap between in vitro and in vivo studies

  • Microfluidic organ-on-chip models: Control environmental parameters while maintaining tissue complexity

  • 3D tissue constructs: Study infection in structured environments

Selecting and combining these models based on specific research questions will provide comprehensive insights into SHMT's multifaceted roles in S. aureus pathogenesis.